Why Orphan Drugs Remain Resilient in a Shifting Market

On March 13 2026, Evaluate published its 2026 Orphan Drug Report.¹ It recounts that rare disease drugs are on track to represent more than 21% of all prescription pharmaceutical sales by 2032, up from 15% in 2022. That translates to over $400 billion in rare disease drug revenues out of a projected $1.9 trillion total prescription market. This trajectory carries direct implications for pipeline prioritization, capacity planning, and investment decisions.

The report draws on forecasts from Evaluate Pharma to make the case that, despite a turbulent policy environment and intense commercial competition from large-indication products, the rare disease segment has demonstrated consistent resilience.¹ "We continue to see drugs for rare diseases cement their place as major players in the overall drug market,"¹ said Andreas Hadjivasiliou, manager of Content Strategy, Evaluate, in a press release. "Their capacity to navigate a changing industry, policy, and regulatory changes while maintaining momentum is something to be noted by developers in this space and in the mainstream drug markets as well."

What Do Recent Policy Shifts Mean for Rare Disease Development?

The policy landscape has shifted in ways that materially affect the commercial calculus for rare disease programs.¹ Until 2025, only single-indication orphan drugs were exempt from price negotiations under the Inflation Reduction Act. Amendments introduced through the current administration's One Big Beautiful Bill have extended those exemptions to multi-indication drugs. Separately, the Rare Pediatric Disease Priority Review Voucher program was reauthorized in early 2026, restoring an incentive mechanism that promises accelerated review timelines for products targeting rare childhood conditions.

Despite these supportive developments, orphan drugs' share of overall prescription sales is expected to decline modestly during the next seven years.¹ The report attributes this in part to a growing commercial focus on high-volume, large-indication products, most notably obesity treatments, a trend driven by the industry's need to address an estimated $300 billion revenue gap created by approaching patent expirations. This reorientation of Big Pharma resources could affect partnering opportunities, contract manufacturing demand, and competitive dynamics in shared therapeutic platform areas.

On the pipeline and commercial front, the report identifies significant near-term concentration at the top of the market.¹ The eight highest-selling orphan drugs are each forecast to exceed $6 billion in sales by 2032, and the collective sales of today's orphan drug pipeline candidates are projected to surpass $100 billion by that year. Johnson & Johnson's Darzalex, indicated for multiple myeloma, is forecast to be the top-selling orphan drug by 2032, with the subcutaneous formulation of the product credited with effectively doubling the franchise's commercial lifespan. Johnson & Johnson is projected to lead all companies in orphan drug revenues, with nearly $31 billion in forecast sales, placing particular manufacturing and supply chain demands on the organization and its partners.

How Do Recent Law Changes Affect Orphan Drug Exclusivity and Review Times?

Two legislative changes signed into law on February 3, 2026 as part of the Consolidated Appropriations Act have added further regulatory stability to the industry.² Together, they restore and clarify incentive structures that directly affect how developers and manufacturers plan rare disease programs.

The Rare Pediatric Disease Priority Review Voucher program has been reauthorized through September 2029.² Under the program, sponsors who secure approval of a therapy for a rare pediatric disease receive a transferable voucher that reduces FDA review time for a subsequent application from 10 months to approximately 6 months. Given that these vouchers have historically sold for over $100 million, reauthorization restores a meaningful financial lever for organizations weighing investment in rare childhood conditions.

The legislation also resolved a long-running legal ambiguity around orphan drug exclusivity.² A 2021 appellate court ruling had threatened to broaden the exclusivity bar to cover an entire rare disease or condition, rather than the specific approved indication. The new law codifies the FDA's narrower interpretation, confirming that exclusivity applies to the approved use or indication within a rare disease, and does so retroactively.

References

1. Evaluate. Evaluate releases 2026 Orphan Drug Report: report reveals that FDA temperament and blockbuster drugs fall short of disrupting the ever-increasing orphan drug market. News release. March 13, 2026. Accessed March 13, 2026.
2. Wilson Sonsini Goodrich & Rosati. Congress reauthorizes the Rare Pediatric Disease Priority Review Voucher Program and clarifies orphan drug exclusivity. February 9, 2026. Accessed March 13, 2026. https://www.wsgr.com/en/insights/congress-reauthorizes-the-rare-pediatric-disease-priority-review-voucher-program-and-clarifies-orphan-drug-exclusivity.html